1. Home
  2. VSAT vs GRFS Comparison

VSAT vs GRFS Comparison

Compare VSAT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSAT

ViaSat Inc.

HOLD

Current Price

$41.60

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.31

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSAT
GRFS
Founded
1986
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
6.2B
IPO Year
1996
2006

Fundamental Metrics

Financial Performance
Metric
VSAT
GRFS
Price
$41.60
$9.31
Analyst Decision
Buy
Hold
Analyst Count
6
2
Target Price
$37.20
$10.15
AVG Volume (30 Days)
1.9M
472.1K
Earning Date
02-05-2026
07-28-2022
Dividend Yield
N/A
1.53%
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
$4,616,074,000.00
$8,821,017,248.00
Revenue This Year
$5.25
$5.36
Revenue Next Year
$3.45
$5.15
P/E Ratio
N/A
$17.88
Revenue Growth
2.07
7.31
52 Week Low
$7.36
$6.19
52 Week High
$49.68
$11.14

Technical Indicators

Market Signals
Indicator
VSAT
GRFS
Relative Strength Index (RSI) 50.64 48.88
Support Level $36.71 $9.23
Resistance Level $49.68 $9.60
Average True Range (ATR) 3.02 0.19
MACD -0.80 0.00
Stochastic Oscillator 38.78 53.61

Price Performance

Historical Comparison
VSAT
GRFS

About VSAT ViaSat Inc.

Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: